X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S. Currently, it is being evaluated in the early-stage clinical trial studies for the treatment of NSCLC.
Lead Product(s): JIN-A02
Therapeutic Area: Oncology Product Name: JIN-A02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2024
Details:
The license agreement is for JIN-A04, an oral Tyrosine Kinase Inhibitor (TKI) targeting non-small cell lung cancer carrying HER2 mutations. There is currently no oral drug approved to date.
Lead Product(s): JIN-A04
Therapeutic Area: Oncology Product Name: JIN-A04
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Yuhan Corporation
Deal Size: $325 million Upfront Cash: $1.9 million
Deal Type: Licensing Agreement May 31, 2023
Details:
JIN-A02 is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC. 'JIN-A02' have a high brain penetrance and is expected to become the most promising 4th-generation EGFR TKI in NSCLC patients with limited or no viable treatment options.
Lead Product(s): JIN-A02
Therapeutic Area: Oncology Product Name: JIN-A02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
JIN-A02 is a novel orally administered EGFR TKI that targets NSCLC cancers harboring C797S mutation, showed strong inhibitory activities against NSCLC cancer cell-lines harboring double and triple mutations with C797S mutations in in-vitro studies.
Lead Product(s): JIN-A02
Therapeutic Area: Oncology Product Name: JIN-A02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
JIN-A02 is a novel orally administered 4th generation EGFR TKI that targets NSCLC cancers harboring C797S mutation. C797S is a mutation that occur after the use of 3rd generation EGFR TKIs such as Osimertinib and Lazertinib, resulting in tumor resistance and disease relapse.
Lead Product(s): JIN-A02
Therapeutic Area: Oncology Product Name: JIN-A02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
